Novo Nordisk stock surges 7% after Ozempic maker’s latest weight loss drug shows promise
The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger.
Novo Nordisk next-gen shot shows 22% weight loss in early results
Novo Nordisk on Friday announced early-stage trial results for its amycretin obesity drug for subcutaneous injection, saying people with obesity or overweight treated with the drug achieved a 22% weight loss after 36 weeks.
Ozempic maker’s stock surges. A trial of a new Novo Nordisk drug shows promise.
Novo Nordisk shares jumped on Friday as the Danish drugmaker said an experimental drug was able to reduce weight by as much as 22%.
Novo Nordisk stock pops on phase I data for new weight-loss drug amycretin
Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 products, by mimicking a hormone in the body that provides a satiated feeling and curbs hunger, but adds a different hormone in the pancreas.
Why Novo Nordisk Stock Jumped a Lucky 7.7% Today
On Friday, however, Novo Nordisk announced top-line results in yet another trial. While the results don't initially sound as good as those in the trials cited above, however, the speed at which they were achieved has investors cheering, and Novo Nordisk stock is up 7.7% through 10:50 a.m. Friday morning.
Novo Nordisk Stock Jumps on Early Stage Weight-Loss Drug Trial Results
Novo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for its amycretin weight-loss drug.
An Ozempic alternative shows promising weight loss results — and Novo Nordisk stock surges 12%
Novo Nordisk (NVO) stock jumped 12% in pre-market trading Friday after it released promising results of an early-stage weight loss drug trial.
Novo Nordisk spikes as novel obesity drug causes up to 22% of weight loss
Novo Nordisk (NVO) stock gains on promising Phase 1/2 data for the drugmaker's new weight loss drug amycretin. Read more here.
The Score: Novo Nordisk, Oracle, Netflix, and More Stocks That Defined the Week
Here are some of the major companies whose stocks moved on the week’s news.
Novo Nordisk Stock Soars on New Weight-Loss Drug Results
Novo Nordisk scored a much-needed win on Friday, with early-stage data on a new weight-loss drug that suggested it could work better than the obesity blockbusters already on the market. Novo American depositary receipt was down 38% in the six months prior to Friday’s announcement,
Novo Nordisk Soars 12% With Ozempic Alternative
Novo Nordisk (NVO) experienced a significant surge in pre-market trading on Friday, with its stock climbing 12% following the announcement of promising results from an early-stage clinical trial for its new obesity treatment,
STAT14h
Novo Nordisk is slammed by U.K. trade group for not disclosing payments to health and patient groups
Novo Nordisk was slammed by a U.K. trade group for not disclosing payments to health and patient groups, according to a draft ...
Will Medicare End Ozempic Maker Novo Nordisk's Obesity Drug Boom?
Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...
Investors who lost money on Novo Nordisk A/S(NVO) should contact Levi & Korsinsky about pending Class Action - NVO
NEW YORK, NY / ACCESS Newswire / January 24, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about ...
STAT15h
Novo Nordisk’s next-generation obesity treatment shows promise in early study
A new weight loss drug from Novo Nordisk helped patients lose a large amount of weight, providing a boost for Novo in the ...
Novo Nordisk and Eli Lilly will dominate the obesity drug market long-term, says Mizuho's Jared Holz
Novo Nordisk and Eli Lilly will dominate the obesity drug market long-term, says Mizuho's Jared Holz Jared Holz, Mizuho, ...
Wall Street edges back from its record
On the winning side of Wall Street were Novo Nordisk’s U.S.-listed shares, which jumped 8.5%. The Danish company reported ...
devdiscourse7h
Breaking Health News: Novo Nordisk's Weight Loss Breakthrough and Purdue Pharma Settlement
The latest health briefs reveal Novo Nordisk's promising obesity treatment and a $7.4 billion Purdue Pharma settlement over ...
MM&M9h
What will happen to Medicare drug pricing negotiations under Trump?
As the next round of Medicare drug pricing negotiations get underway, experts predict President Trump may seek to weaken the program.